mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levels
Sandra E. Ghayad(Inserm), Pascale A. Cohen(Lyon 1 Université), Julie A. Vendrell(Inserm), Charles Dumontet(Centre de Recherche en Cancérologie de Lyon), Rosette Lidereau(Inserm), Céline Keime(Centre National de la Recherche Scientifique), Ivan Bièche(Centre National de la Recherche Scientifique)
Cited by 76
Related Papers
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2024|343
Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
|Endocrine Reviews|2011|302